Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia

Anna Maria Frustaci, Alessandra Tedeschi, Paola Picardi, Roberto Cairoli, Marco MontilloDepartment of Hematology, Niguarda Cancer Center, Niguarda Ca' Granda Hospital, Milan, Italy Abstract: Treatment aim for chronic lymphocytic leukemia has been radically changed over the past years from p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Frustaci AM, Tedeschi A, Picardi P, Cairoli R, Montillo M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/338dbfaba9a843b1932eb2d55b9de2cb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:338dbfaba9a843b1932eb2d55b9de2cb
record_format	dspace
spelling	oai:doaj.org-article:338dbfaba9a843b1932eb2d55b9de2cb2021-12-02T06:07:44ZClinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia1177-5491https://doaj.org/article/338dbfaba9a843b1932eb2d55b9de2cb2015-09-01T00:00:00Zhttps://www.dovepress.com/clinical-utility-and-patient-considerations-in-the-use-of-ofatumumab-i-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Anna Maria Frustaci, Alessandra Tedeschi, Paola Picardi, Roberto Cairoli, Marco MontilloDepartment of Hematology, Niguarda Cancer Center, Niguarda Ca' Granda Hospital, Milan, Italy Abstract: Treatment aim for chronic lymphocytic leukemia has been radically changed over the past years from providing only a palliative approach to reaching disease eradication and improving survival. Ofatumumab is a monoclonal humanized antibody with peculiar in vitro and in vivo properties, at present approved for double fludarabine and alemtuzumab refractory chronic lymphocytic leukemia. Its efficacy in this subset of patients, who typically have an unfavorable prognosis, facilitated its use in different Phase II and III trials. Ofatumumab as single agent or combined with chemotherapeutic or biologic agents, led to sundry results in the setting of both previously treated or untreated patients. Its role in maintenance therapy is also under investigation. Further advances concerning ofatumumab administration as first line therapy in combination with chlorambucil, came recently from the COMPLEMENT 1 study. Results from this trial will open the door to new perspectives of its use in treatment-naïve patients. Ofatumumab was well tolerated in almost all the studies, with the main adverse events relating mostly to infusion reaction. Hematologic toxicity, especially neutropenia, was also common. A significant improvement in patients' quality of life was reported following ofatumumab treatment and this was mainly due to its effect on constitutional symptoms. Nevertheless, some concerns remain regarding the long-term efficacy of the drug in terms of response duration and survival. The real strength of this drug needs to be confirmed by further studies and direct comparative trials. Keywords: ofatumumab, chronic lymphocytic leukemia, refractory, alemtuzumab, fludarabine, high riskFrustaci AMTedeschi APicardi PCairoli RMontillo MDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2015, Iss default, Pp 75-86 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Frustaci AM Tedeschi A Picardi P Cairoli R Montillo M Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
description	Anna Maria Frustaci, Alessandra Tedeschi, Paola Picardi, Roberto Cairoli, Marco MontilloDepartment of Hematology, Niguarda Cancer Center, Niguarda Ca' Granda Hospital, Milan, Italy Abstract: Treatment aim for chronic lymphocytic leukemia has been radically changed over the past years from providing only a palliative approach to reaching disease eradication and improving survival. Ofatumumab is a monoclonal humanized antibody with peculiar in vitro and in vivo properties, at present approved for double fludarabine and alemtuzumab refractory chronic lymphocytic leukemia. Its efficacy in this subset of patients, who typically have an unfavorable prognosis, facilitated its use in different Phase II and III trials. Ofatumumab as single agent or combined with chemotherapeutic or biologic agents, led to sundry results in the setting of both previously treated or untreated patients. Its role in maintenance therapy is also under investigation. Further advances concerning ofatumumab administration as first line therapy in combination with chlorambucil, came recently from the COMPLEMENT 1 study. Results from this trial will open the door to new perspectives of its use in treatment-naïve patients. Ofatumumab was well tolerated in almost all the studies, with the main adverse events relating mostly to infusion reaction. Hematologic toxicity, especially neutropenia, was also common. A significant improvement in patients' quality of life was reported following ofatumumab treatment and this was mainly due to its effect on constitutional symptoms. Nevertheless, some concerns remain regarding the long-term efficacy of the drug in terms of response duration and survival. The real strength of this drug needs to be confirmed by further studies and direct comparative trials. Keywords: ofatumumab, chronic lymphocytic leukemia, refractory, alemtuzumab, fludarabine, high risk
format	article
author	Frustaci AM Tedeschi A Picardi P Cairoli R Montillo M
author_facet	Frustaci AM Tedeschi A Picardi P Cairoli R Montillo M
author_sort	Frustaci AM
title	Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
title_short	Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
title_full	Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
title_fullStr	Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
title_full_unstemmed	Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
title_sort	clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/338dbfaba9a843b1932eb2d55b9de2cb
work_keys_str_mv	AT frustaciam clinicalutilityandpatientconsiderationsintheuseofofatumumabinchroniclymphocyticleukemia AT tedeschia clinicalutilityandpatientconsiderationsintheuseofofatumumabinchroniclymphocyticleukemia AT picardip clinicalutilityandpatientconsiderationsintheuseofofatumumabinchroniclymphocyticleukemia AT cairolir clinicalutilityandpatientconsiderationsintheuseofofatumumabinchroniclymphocyticleukemia AT montillom clinicalutilityandpatientconsiderationsintheuseofofatumumabinchroniclymphocyticleukemia
_version_	1718400044886917120

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia

Ejemplares similares